Business News • MarketWire • Ares Life Sciences Acquires 45.86% Stake in Stallergenes and Plans Mandatory Takeover Offer for All Remaining Outstanding Shares

Ares Life Sciences Acquires 45.86% Stake in Stallergenes and Plans Mandatory Takeover Offer for All Remaining Outstanding Shares

Ares Life Sciences Acquires 45.86% Stake in Stallergenes and Plans Mandatory Takeover Offer for All Remaining Outstanding Shares

GENEVA, SWITZERLAND--(Marketwire - Nov. 17, 2010) - Ares Life Sciences, a health care investment firm established by the Bertarelli family announces that it has acquired Wendel's equity interest in Stallergenes, representing 45.86% of the share capital and voting rights of Stallergenes, at a price of ?59.00 per share.

View More : http://www.marketwire.com/mw/release.do?id=1354942&sourceType=3

Releted News by marketwire

Ares Life Sciences acquiert 45,86% de Stallergenes et se prépare à lancer une offre publique d'achat obligatoire sur les actions Stallergenes restant en circulation

Experian plc announces Half Yearly Report